Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease. (Q37087146)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18281732%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

review article

1 reference

title

Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18281732%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18281732%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Javier Peral

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18281732%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Oihana Mora

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18281732%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Saioa Domingo-Echaburu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18281732%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

María Jose Martínez-Bengoechea

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18281732%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Juan Carlos García-Moncó

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18281732%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

1 March 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18281732%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Health-System Pharmacy

2 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18281732%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18281732%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18281732%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

414-419

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18281732%20AND%20SRC:MED&resulttype=core&format=json

Epidemiology of Parkinson's disease

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Treatment of psychosis in Parkinson's disease: safety considerations

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Long-term outcome of clozapine use for psychosis in parkinsonian patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Modulatory effect of clozapine on levodopa response in Parkinson's disease: a preliminary study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Reply to "Question the experts"

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Clozapine treatment of parkinsonism with psychosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Clozapine and risperidone treatment of psychosis in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Risperidone treatment of drug-related psychosis in patients with parkinsonism

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Risperidone in levodopa‐induced psychosis in advanced parkinson's disease: An open‐label, long‐term study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Olanzapine treatment for dopaminergic-induced hallucinations

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Worsening of motor features of parkinsonism with olanzapine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Efficacy of quetiapine in Parkinson's patients with psychosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Quetiapine improves psychotic symptoms and cognition in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Use of ziprasidone in parkinsonian patients with psychosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Pisa syndrome and atypical antipsychotics

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Aripiprazole in psychosis associated with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Domperidone: a peripherally acting dopamine2-receptor antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Apomorphine in the treatment of Parkinson's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Quick titration of pergolide in cotreatment with domperidone is safe and effective.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Bromocriptine and domperidone in the treatment of Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Intranasal apomorphine rescue therapy for parkinsonian "off" periods.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Structure side-effect sorting of drugs. I. Extrapyramidal syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Trimethobenzamide HCL (Tigan)-induced extrapyramidal dysfunction in a neonate

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Hiccups associated with dopamine agonists in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Treatment of intractable hiccup in haemodialysis patients with baclofen

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

Baclofen therapy for intractable hiccups induced by ultraflex esophageal endoprosthesis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

A renal transplant patient with intractable hiccups and review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060624

31 March 2020

Identifiers

DOI

10.2146/AJHP060624

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18281732%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18281732%20AND%20SRC:MED&resulttype=core&format=json